Grace Therapeutics (GRCE) Tax Provisions (2022 - 2026)
Grace Therapeutics (GRCE) posted Tax Provisions of -$1.7 million for Q1 2026, down 240.0% sequentially from -$500000.0 in Q1 2025, and down 240.0% YoY from $1.2 million in Q1 2025.
Grace Therapeutics (GRCE) Tax Provisions (2022 - 2026) Analysis & Trends
Grace Therapeutics has reported Tax Provisions for 5 years, with the latest figure at -$1.7 million in Q1 2026.
- Quarterly Tax Provisions fell 240.0% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.7 million (up 36.59% YoY) and the FY2026 annual result came in at -$1.7 million, up 36.59% from the prior year.
- Tax Provisions retreated to -$1.7 million in Q1 2026 per GRCE's latest filing, from -$500000.0 in the prior quarter.
- Over five years, Tax Provisions peaked at $671000.0 in Q1 2023 and troughed at -$2.8 million in Q1 2022.
- A 5-year average of -$535428.6 and a median of -$367500.0 in 2023 frame the typical range for Tax Provisions.
- The sharpest annual moves came in 2023 and 2026: Tax Provisions soared 124.19% in 2023, then plunged 240.0% in 2026.
- Over 5 years, Tax Provisions stood at -$274000.0 in 2022, then advanced by 24.09% to -$208000.0 in 2023, then tumbled by 190.87% to -$605000.0 in 2024, then grew by 17.36% to -$500000.0 in 2025, then slumped by 240.0% to -$1.7 million in 2026.
- According to Business Quant data, Tax Provisions over the past three periods registered -$1.7 million, -$500000.0, and -$605000.0 for Q1 2026, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.31 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.90 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -90.33 Mn |
| 10 | Grace Therapeutics | 37.04 Mn | 37.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.70 Mn |
| Mar 31, 2025 | -500,000.00 |
| Dec 31, 2024 | -605,000.00 |
| Sep 30, 2024 | -852,000.00 |
| Jun 30, 2024 | -724,000.00 |
| Mar 31, 2024 | 602,000.00 |
| Dec 31, 2023 | -208,000.00 |
| Sep 30, 2023 | -446,000.00 |
| Jun 30, 2023 | -289,000.00 |
| Mar 31, 2023 | 671,000.00 |
| Dec 31, 2022 | -274,000.00 |
| Sep 30, 2022 | -155,000.00 |
| Jun 30, 2022 | -242,000.00 |
| Mar 31, 2022 | -2.77 Mn |